SCHEMBL8069094

SCHEMBL8069094

COc1ccc2c(c1)nc(C)n2-c1cnc(NC(=O)c2c(C)cccc2F)cn1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
STIM1 Q13586 1/20 0.43
ORAI1 Q96D31 1/20 0.43
ORAI2 Q96SN7 1/20 0.43
THRB P10828 2/20 0.42
RAB9A P51151 3/20 0.41
NPC1 O15118 2/20 0.40
CYP1A2 P05177 1/20 0.40
HSD17B10 Q99714 2/20 0.39
LMNA P02545 1/20 0.39
MAPT P10636 1/20 0.39
NFKB1 P19838 1/20 0.39
NFKB2 Q00653 1/20 0.39
RELA Q04206 1/20 0.39
HSP90AA1 P07900 1/20 0.39
HSP90AB1 P08238 1/20 0.39
PIK3CD O00329 1/20 0.39
PIK3CA P42336 1/20 0.39
BRD4 O60885 1/20 0.38
GRM5 P41594 1/20 0.38
MEN1 O00255 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3103400 0.95 RAB9A (0.45) THRBRAB9ANPC1CYP1A2HSD17B10
SCHEMBL8069504 0.91 STIM1 (0.46) STIM1ORAI1ORAI2RAB9ANPC1
SCHEMBL3104227 0.86 RAB9A (0.44) STIM1ORAI1ORAI2RAB9ANPC1
SCHEMBL647154 0.84 RAB9A (0.43) RAB9ANPC1CYP1A2MAPTMEN1
SCHEMBL8236747 0.82 NPC1 (0.46) THRBRAB9ANPC1HSD17B10LMNA
SCHEMBL8234041 0.82 NPC1 (0.39) THRBRAB9ANPC1HSD17B10MAPT
SCHEMBL8055351 0.81 IL2 (0.42) STIM1ORAI1ORAI2IL2ABL1
SCHEMBL8234426 0.81 RAB9A (0.45) THRBRAB9ANPC1HSD17B10LMNA
SCHEMBL8236417 0.81 RAB9A (0.51) THRBRAB9ANPC1HSD17B10LMNA
SCHEMBL8234051 0.81 ALOX15 (0.49) THRBCYP1A2HSD17B10MAPTGRM5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2009038775-A1 SUBSTITUTED BENZOIMIDAZOLYL-PYRAZINE COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES SYNTA PHARMACEUTICALS CORP. (US) 2009-03-26 WO disclosed